Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

withdrawn3100%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00024115
withdrawnphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403
withdrawnphase_2

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

NCT00017160

Clinical Trials (3)

Showing 3 of 3 trials
NCT00024115Phase 1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Withdrawn
NCT00052403Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Withdrawn
NCT00017160Phase 2

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3